MarketCapExport financials
Unity Biotechnology (UBX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Unity Biotechnology Balance Sheet 2024-2011 | UBX
Brief overview of Unity Biotechnology's financial position
This overview follows the five latest available annual observations between 2020 and 2024.
Across five reporting periods, assets decreased -75.9%, from $156.3 million to $37.7 million, producing a negative trend.
Funding shifted toward liabilities: they gained -57.6%, compared with -75.9% for assets.
The equity ratio equals 17.2%, with a starting level of 53%. Stable cash flow is important under this structure.
Net debt exceeds equity by 2.46x. The burden makes the balance sheet sensitive to earnings, rates and cash flow.
Cash accounts for 20.1% of assets versus 11.4% initially. The change indicates the degree of financial flexibility.
The balance sheet carries negative retained earnings of -$510.3 million. The figure may result from accumulated losses or an active capital return policy.
Overall picture
Unity Biotechnology's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Unity Biotechnology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
16 M | 7.19 M | 1.26 M | -10.1 M | 11.2 M | -37.4 M | -15.3 M | -7.3 M | -89.3 M | - | - | - | - | - |
Long Term Debt |
19.7 M | 23.5 M | 10.9 M | 18.4 M | 24.5 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.83 M | 3.45 M | 3.1 M | 4.38 M | 4.52 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 13.3 M | 4.1 M | 3.28 M | 134 M | - | - | - | - | - |
Total Current Liabilities |
9.26 M | 7.84 M | 19.6 M | 16.6 M | 14.5 M | 17.2 M | 16.6 M | - | - | - | - | - | - | - |
Total Liabilities |
31.2 M | 37.3 M | 68.3 M | 65.1 M | 73.4 M | 30.5 M | 20.7 M | 11.2 M | 138 M | - | - | - | - | - |
Retained Earnings |
-510 M | -484 M | -444 M | -400 M | - | -245 M | -163 M | -86.9 M | -42.2 M | - | - | - | - | - |
Total Assets |
37.7 M | 65.7 M | 124 M | 125 M | 156 M | 151 M | 181 M | 102 M | 96.6 M | - | - | - | - | - |
Cash and Cash Equivalents |
7.58 M | 19.8 M | 12.7 M | 32.9 M | 17.8 M | 37.5 M | 15.4 M | 7.3 M | 89.7 M | - | - | - | - | - |
Book Value |
6.49 M | 28.4 M | 56.1 M | 59.6 M | 82.9 M | 121 M | 161 M | 90.8 M | -41.5 M | - | - | - | - | - |
Total Shareholders Equity |
6.49 M | 28.4 M | 56.1 M | 59.6 M | 82.9 M | 121 M | 161 M | -83.1 M | -41.5 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Unity Biotechnology
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
18.7 M | 19.7 M | 20.7 M | 21.7 M | 22.6 M | 23.5 M | - | 4.08 M | 7.62 M | 10.9 M | 13.3 M | 12.7 M | 14.5 M | 18.4 M | 24.1 M | 24.9 M | 24.7 M | 24.5 M | 24.5 M | 24.5 M | 24.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
30.6 M | 31.2 M | 33 M | 33.8 M | 34.9 M | 37.3 M | 33.1 M | 51.6 M | 55.6 M | 57.5 M | 57.8 M | 57.7 M | 61.8 M | 65.1 M | 68 M | 70.3 M | 68.2 M | 73.4 M | 73.4 M | 73.4 M | 73.4 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 216 K | 216 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-518 M | -510 M | -502 M | -495 M | -490 M | -484 M | -498 M | -483 M | -471 M | -460 M | -446 M | -432 M | -419 M | -400 M | -389 M | -373 M | -355 M | -339 M | -339 M | -339 M | -339 M | -245 M | -245 M | -245 M | -245 M | -163 M | -163 M | -163 M | -163 M | -86.9 M | -86.9 M | -86.9 M | -86.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
30.3 M | 37.7 M | 47.1 M | 53.5 M | 58.9 M | 65.7 M | 69.3 M | 101 M | 114 M | 124 M | 136 M | 97.6 M | 112 M | 125 M | 126 M | 136 M | 148 M | 156 M | 156 M | 156 M | 156 M | 151 M | 151 M | 151 M | 151 M | 181 M | 181 M | 181 M | 181 M | 102 M | 102 M | 102 M | 102 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
8 M | 7.58 M | 8.9 M | 7.58 M | 7.43 M | 19.8 M | 7.88 M | 19.1 M | 23 M | 12.7 M | 22.6 M | 19.4 M | 16.4 M | 32.9 M | 22 M | 13.5 M | 26.8 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 89.3 M | - | - | - | 940 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-205 K | 6.49 M | 14.1 M | 19.8 M | 24 M | 28.4 M | 36.2 M | 49.4 M | 58.6 M | 66.8 M | 78.6 M | 39.9 M | 50.7 M | 59.6 M | 57.7 M | 65.9 M | 80 M | 82.9 M | 82.9 M | 82.9 M | 82.9 M | 121 M | 121 M | 121 M | 121 M | 161 M | 161 M | 161 M | 161 M | 90.8 M | 90.8 M | 90.8 M | 90.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-205 K | 6.49 M | 14.1 M | 19.8 M | 24 M | 28.4 M | 27.7 M | 40.8 M | 53.4 M | 66.8 M | 78.6 M | 39.9 M | 50.7 M | 59.6 M | 57.7 M | 65.9 M | 80 M | 82.9 M | 82.9 M | 82.9 M | 82.9 M | 121 M | 121 M | 121 M | 121 M | 161 M | 161 M | 161 M | 161 M | -83.1 M | -83.1 M | -83.1 M | -83.1 M | -41.5 M | - | - | - | -11.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Unity Biotechnology, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Israel
Niderland
Australia
Danmark
Canada
Irlanda
